Traws Pharma, Inc. financial data

Symbol
TRAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
12 Penns Trail, Newtown, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
Onconova Therapeutics, Inc. (to 4/1/2024), ONCONOVA THERAPEUTICS INC (to 5/26/2009)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 180 % -42.4%
Operating Margin -63K % -601%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.07M shares -79.9%
Common Stock, Shares, Outstanding 3.65M shares +334%
Entity Public Float 9.6M USD -61%
Common Stock, Value, Issued 36K USD +300%
Weighted Average Number of Shares Outstanding, Basic 1.55M shares +84.9%
Weighted Average Number of Shares Outstanding, Diluted 1.55M shares +84.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 226K USD 0%
Revenue from Contract with Customer, Excluding Assessed Tax 57K USD 0%
Research and Development Expense 9.26M USD -31.3%
General and Administrative Expense 12.3M USD +35.1%
Operating Income (Loss) -142M USD -601%
Net Income (Loss) Attributable to Parent -8.48M USD -78.8%
Earnings Per Share, Basic -35.2 USD/shares -56%
Earnings Per Share, Diluted -35.2 USD/shares -56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.6M USD -46.6%
Other Assets, Current 178K USD -55.6%
Assets, Current 25M USD +10.1%
Property, Plant and Equipment, Net 10K USD -54.5%
Other Assets, Noncurrent 1K USD 0%
Assets 25M USD +10%
Accounts Payable, Current 8.19M USD +45.7%
Employee-related Liabilities, Current 265K USD -73.6%
Accrued Liabilities, Current 3.12M USD -7.53%
Contract with Customer, Liability, Current 226K USD 0%
Liabilities, Current 11.5M USD +25.1%
Contract with Customer, Liability, Noncurrent 2.57M USD -8.1%
Liabilities 56.6M USD +371%
Accumulated Other Comprehensive Income (Loss), Net of Tax -42K USD -82.6%
Retained Earnings (Accumulated Deficit) -649M USD -34.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -31.6M USD -396%
Liabilities and Equity 25M USD +10%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.42M USD +2.62%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 3.65M shares +334%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.43M USD +2.34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.3M USD +2.48%
Deferred Tax Assets, Valuation Allowance 36.8M USD -78.9%
Deferred Tax Assets, Gross 36.8M USD -78.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.48M USD -78.8%
Property, Plant and Equipment, Gross 84K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 28.3M USD -61.7%
Preferred Stock, Shares Issued 7.44K shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 7.4K shares
Depreciation, Depletion and Amortization 4K USD +33.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.39M USD +6.84%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%